Education
About Us
Working with TipRanks
Follow Us
Medivir AB (SE:MVIR)
:MVIR
MVIR Stock Chart & Stats
kr1.35
--
Market closed
kr1.35
--
Day’s Range― - ―
52-Week Rangekr0.34 - kr2.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)783.39K
Market Cap
kr655.04M
Enterprise Valuekr144.18M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding448,671,230
10 Day Avg. Volume1,906,950
30 Day Avg. Volume783,395
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medivir AB News
MVIR FAQ
What was Medivir AB’s price range in the past 12 months?
Medivir AB lowest stock price was kr0.34 and its highest was kr2.22 in the past 12 months.
What is Medivir AB’s market cap?
Medivir AB’s market cap is kr655.04M.
When is Medivir AB’s upcoming earnings report date?
Medivir AB’s upcoming earnings report date is Apr 29, 2026 which is in 67 days.
How were Medivir AB’s earnings last quarter?
Medivir AB released its earnings results on Feb 18, 2026. The company reported -kr0.19 earnings per share for the quarter, beating the consensus estimate of -kr0.375 by kr0.185.
Is Medivir AB overvalued?
According to Wall Street analysts Medivir AB’s price is currently Overvalued.
Does Medivir AB pay dividends?
Medivir AB does not currently pay dividends.
What is Medivir AB’s EPS estimate?
Medivir AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medivir AB have?
Medivir AB has 448,671,230 shares outstanding.
What happened to Medivir AB’s price movement after its last earnings report?
Medivir AB reported an EPS of -kr0.19 in its last earnings report, beating expectations of -kr0.375. Following the earnings report the stock price went up 46%.
Which hedge fund is a major shareholder of Medivir AB?
Currently, no hedge funds are holding shares in SE:MVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medivir AB
Medivir AB is pharmaceutical research and development company. It develops pharmaceuticals for the treatment of cancer and specializes in protease inhibitor research and nucleotide science. The firm conducts research in all phases of pharmaceutical development from idea to clinical phase III studies. Its project pipeline includes Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323 proprietary projects and also Olysio, JNJ-4178, Xerclear and MIV-802 partnership projects. The firm's products include Xerclear and Simprevir.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Active Biotech AB
―